These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

454 related articles for article (PubMed ID: 27089329)

  • 1. Linkers Having a Crucial Role in Antibody-Drug Conjugates.
    Lu J; Jiang F; Lu A; Zhang G
    Int J Mol Sci; 2016 Apr; 17(4):561. PubMed ID: 27089329
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Methods to Design and Synthesize Antibody-Drug Conjugates (ADCs).
    Yao H; Jiang F; Lu A; Zhang G
    Int J Mol Sci; 2016 Feb; 17(2):. PubMed ID: 26848651
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tubulin Inhibitor-Based Antibody-Drug Conjugates for Cancer Therapy.
    Chen H; Lin Z; Arnst KE; Miller DD; Li W
    Molecules; 2017 Aug; 22(8):. PubMed ID: 28763044
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antibody-Drug Conjugates (ADCs) Derived from Interchain Cysteine Cross-Linking Demonstrate Improved Homogeneity and Other Pharmacological Properties over Conventional Heterogeneous ADCs.
    Behrens CR; Ha EH; Chinn LL; Bowers S; Probst G; Fitch-Bruhns M; Monteon J; Valdiosera A; Bermudez A; Liao-Chan S; Wong T; Melnick J; Theunissen JW; Flory MR; Houser D; Venstrom K; Levashova Z; Sauer P; Migone TS; van der Horst EH; Halcomb RL; Jackson DY
    Mol Pharm; 2015 Nov; 12(11):3986-98. PubMed ID: 26393951
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antibody-drug conjugates for the treatment of cancer.
    Flygare JA; Pillow TH; Aristoff P
    Chem Biol Drug Des; 2013 Jan; 81(1):113-21. PubMed ID: 23253133
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthesis, characterization, and targeted chemotherapy of SCT200-linker-monomethyl auristatin E conjugates.
    Hu X; Jiang H; Bai W; Liu X; Miao Q; Wang L; Jin J; Cui A; Liu R; Li Z
    Eur J Med Chem; 2021 Apr; 216():113297. PubMed ID: 33677351
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antibody drug conjugates.
    Bakhtiar R
    Biotechnol Lett; 2016 Oct; 38(10):1655-64. PubMed ID: 27334710
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel linkers and connections for antibody-drug conjugates to treat cancer and infectious disease.
    Pillow TH
    Pharm Pat Anal; 2017 Jan; 6(1):25-33. PubMed ID: 28155578
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Marine Antibody-Drug Conjugates: Design Strategies and Research Progress.
    Wang YJ; Li YY; Liu XY; Lu XL; Cao X; Jiao BH
    Mar Drugs; 2017 Jan; 15(1):. PubMed ID: 28098746
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cleavable linkers in antibody-drug conjugates.
    Bargh JD; Isidro-Llobet A; Parker JS; Spring DR
    Chem Soc Rev; 2019 Aug; 48(16):4361-4374. PubMed ID: 31294429
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficient Preparation of Site-Specific Antibody-Drug Conjugates Using Cysteine Insertion.
    Dimasi N; Fleming R; Zhong H; Bezabeh B; Kinneer K; Christie RJ; Fazenbaker C; Wu H; Gao C
    Mol Pharm; 2017 May; 14(5):1501-1516. PubMed ID: 28245132
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antibody drug conjugates: Progress, pitfalls, and promises.
    Mukherjee A; Waters AK; Babic I; Nurmemmedov E; Glassy MC; Kesari S; Yenugonda VM
    Hum Antibodies; 2019; 27(1):53-62. PubMed ID: 30223393
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antibody-drug conjugates: an emerging modality for the treatment of cancer.
    Leal M; Sapra P; Hurvitz SA; Senter P; Wahl A; Schutten M; Shah DK; Haddish-Berhane N; Kabbarah O
    Ann N Y Acad Sci; 2014 Aug; 1321():41-54. PubMed ID: 25123209
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recent Chemical Approaches for Site-Specific Conjugation of Native Antibodies: Technologies toward Next-Generation Antibody-Drug Conjugates.
    Yamada K; Ito Y
    Chembiochem; 2019 Nov; 20(21):2729-2737. PubMed ID: 30973187
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Chemical Design and Synthesis of Linkers Used in Antibody Drug Conjugates.
    Frigerio M; Kyle AF
    Curr Top Med Chem; 2017; 17(32):3393-3424. PubMed ID: 29357801
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Novel Chemical Linkers for Next-generation Antibody-drug Conjugates(ADCs)].
    Tsuchikama K
    Yakugaku Zasshi; 2019; 139(2):209-219. PubMed ID: 30713230
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular Basis of Valine-Citrulline-PABC Linker Instability in Site-Specific ADCs and Its Mitigation by Linker Design.
    Dorywalska M; Dushin R; Moine L; Farias SE; Zhou D; Navaratnam T; Lui V; Hasa-Moreno A; Casas MG; Tran TT; Delaria K; Liu SH; Foletti D; O'Donnell CJ; Pons J; Shelton DL; Rajpal A; Strop P
    Mol Cancer Ther; 2016 May; 15(5):958-70. PubMed ID: 26944918
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Trends in cancer-targeted antibody-drug conjugates.
    Bidard FC; Trédan O
    Target Oncol; 2014 Mar; 9(1):1-8. PubMed ID: 24221961
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hydrophilic Sequence-Defined Cross-Linkers for Antibody-Drug Conjugates.
    Walker JA; Sorkin MR; Ledesma F; Kabaria SR; Barfield RM; Rabuka D; Alabi CA
    Bioconjug Chem; 2019 Nov; 30(11):2982-2988. PubMed ID: 31671265
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antibody-drug conjugates: a mini-review. The synopsis of two approved medicines.
    Papachristos A; Pippa N; Demetzos C; Sivolapenko G
    Drug Deliv; 2016 Jun; 23(5):1662-6. PubMed ID: 25625494
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.